Product Information

IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Mylan Institutional LLC, priced at $2.8764 per EA under NDC 42292004403. Its NADAC has been published 452 times since Dec 27, 2017.

FDA first approved this application on Jun 21, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IMATINIB MESYLATE 400 MG TAB

imatinib
$2.8764per EA

Strength

400 mg/1

NDC

42292004403

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA204644

FDA Approved

6/21/2017

TE Code

AB

On Market Since

9/7/2017

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 452 times since Dec 27, 2017, and over the history we have for it it has declined 97.7%. The table below summarizes its recorded NADAC range and movement.

Current price$2.8764 per EA
All-time high$123.6453 (Jan 10, 2018)
All-time low$1.4080 (Aug 23, 2023)
52-week high$3.2150
52-week low$2.8764
Median price$3.1988
Average price$10.7226
Largest weekly change+100.9% (Mar 18, 2020)
Weeks tracked452
Tracking sinceDec 27, 2017

Price History

1W

-0.9%

1M

-0.9%

3M

-4.7%

6M

-10.5%

1Y

-5.4%

3Y

+75.8%

5Y

-25.6%

All

-97.7%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Mylan Institutional LLC, is $2.8764 per EA (NDC 42292004403), effective Aug 19, 2026.

How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 97.7%. It has been tracked across 452 weekly CMS publications since Dec 27, 2017.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?

Since Dec 27, 2017, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $1.4080 (Aug 23, 2023) to a high of $123.6453 (Jan 10, 2018), with a median of $3.1988 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as IMATINIB MESYLATE 400 MG TAB in a comparable dosage form, but none are currently priced below it.

Who manufactures IMATINIB MESYLATE 400 MG TAB?

IMATINIB MESYLATE 400 MG TAB (NDC 42292004403) is labeled by Mylan Institutional LLC, and CMS classifies it as a generic product.